Back to Directory
Errigal Bio
Northern Ireland
Founded 2025
Discovery platform targeting therapy-induced antigens driving cancer relapse
Errigal Bio is an oncology-focused drug discovery company developing a platform that identifies therapy-induced antigen targets arising in cancer cells that survive standard treatment.
The company's approach is based on the premise that these surviving tumour cells carry exploitable vulnerabilities created by the treatment itself, offering a route to targeted therapies aimed specifically at preventing cancer relapse.
Errigal Bio is part of the Francis Crick Institute's KQ Labs venture programme.